OKYO Pharma LtdNASDAQ:OKYO
- LAST PRICE1.0800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.0400/ 1
- Ask / Lots1.1700/ 1
- Open / Previous Close--- / 1.0800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OKYO |
|---|---|---|
| 09:32 ET | 5003 | 1.07 |
| 09:39 ET | 125 | 1.0759 |
| 09:48 ET | 600 | 1.05 |
| 09:55 ET | 200 | 1.05 |
| 10:20 ET | 800 | 1.0556 |
| 10:29 ET | 5221 | 1.12 |
| 10:31 ET | 220 | 1.0886 |
| 10:42 ET | 100 | 1.08 |
| 10:51 ET | 420 | 1.0892 |
| 11:00 ET | 500 | 1.0819 |
| 11:12 ET | 186 | 1.0892 |
| 11:39 ET | 2000 | 1.1199 |
| 11:41 ET | 2500 | 1.0972 |
| 12:01 ET | 100 | 1.09 |
| 12:42 ET | 100 | 1.0706 |
| 12:57 ET | 100 | 1.1 |
| 01:04 ET | 1000 | 1.07 |
| 01:13 ET | 500 | 1.0971 |
| 01:15 ET | 200 | 1.095 |
| 01:22 ET | 1239 | 1.08 |
| 01:31 ET | 100 | 1.075 |
| 01:51 ET | 124 | 1.075 |
| 02:07 ET | 2100 | 1.08 |
| 03:01 ET | 100 | 1.0788 |
| 03:26 ET | 100 | 1.0712 |
| 03:30 ET | 400 | 1.08 |
| 03:32 ET | 100 | 1.08 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
OKYO Pharma Ltd | 36.5M | -1.5x | --- |
Immix Biopharma Inc | 47.2M | -2.0x | --- |
CalciMedica Inc | 47.0M | -1.9x | --- |
Xilio Therapeutics Inc | 47.5M | -0.5x | --- |
Intensity Therapeutics Inc | 46.7M | -3.1x | --- |
Rallybio Corp | 46.1M | -0.7x | --- |
Company Information
OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Contact Information
- Headquarters
- Floor 4, 14/15 Conduit StLONDON, United Kingdom W1S 2XJ
- Phone
- 207-495-2379
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.71 |
Book Value | $-0.08 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
